1. Home
  2. AYTU vs RDHL Comparison

AYTU vs RDHL Comparison

Compare AYTU & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aytu BioPharma Inc.

AYTU

Aytu BioPharma Inc.

HOLD

Current Price

$2.78

Market Cap

23.4M

Sector

Health Care

ML Signal

HOLD

Logo Redhill Biopharma Ltd.

RDHL

Redhill Biopharma Ltd.

HOLD

Current Price

$1.27

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AYTU
RDHL
Founded
N/A
2009
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.4M
5.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AYTU
RDHL
Price
$2.78
$1.27
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$9.33
N/A
AVG Volume (30 Days)
141.4K
1.3M
Earning Date
02-11-2026
09-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$63,696,000.00
$9,550,000.00
Revenue This Year
N/A
$381.91
Revenue Next Year
$47.32
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
157.62
52 Week Low
$0.95
$0.91
52 Week High
$3.07
$6.80

Technical Indicators

Market Signals
Indicator
AYTU
RDHL
Relative Strength Index (RSI) 65.55 55.48
Support Level $2.65 $0.91
Resistance Level $3.07 $1.42
Average True Range (ATR) 0.18 0.09
MACD 0.02 0.02
Stochastic Oscillator 65.73 70.89

Price Performance

Historical Comparison
AYTU
RDHL

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

Share on Social Networks: